

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bolzon Bradley J PhD</u> (Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG [CRSP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/28/2021	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	06/28/2021		s ⁽¹⁾		3,216	D	\$150.6503 ⁽²⁾	17,159	D	
Common Shares	06/28/2021		s ⁽¹⁾		1,578 ⁽³⁾	D	\$150.6503 ⁽²⁾	167,253	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		6,403	D	\$151.4949 ⁽⁵⁾	10,756	D	
Common Shares	06/28/2021		s ⁽¹⁾		3,144 ⁽³⁾	D	\$151.4949 ⁽⁵⁾	164,109	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		3,139	D	\$152.3763 ⁽⁶⁾	7,617	D	
Common Shares	06/28/2021		s ⁽¹⁾		1,540 ⁽³⁾	D	\$152.3763 ⁽⁶⁾	162,569	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		4,519	D	\$153.5389 ⁽⁷⁾	3,098	D	
Common Shares	06/28/2021		s ⁽¹⁾		2,218 ⁽³⁾	D	\$153.5389 ⁽⁷⁾	160,351	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		2,281	D	\$154.5656 ⁽⁸⁾	817	D	
Common Shares	06/28/2021		s ⁽¹⁾		1,119 ⁽³⁾	D	\$154.5656 ⁽⁸⁾	159,232	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		268	D	\$155.2725 ⁽⁹⁾	549	D	
Common Shares	06/28/2021		s ⁽¹⁾		132 ⁽³⁾	D	\$155.2725 ⁽⁹⁾	159,100	I	See Footnote ⁽⁴⁾
Common Shares	06/28/2021		s ⁽¹⁾		549	D	\$156.5414 ⁽¹⁰⁾	0	D	
Common Shares	06/28/2021		s ⁽¹⁾		269 ⁽³⁾	D	\$156.5414 ⁽¹⁰⁾	158,831	I	See Footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$150.00 to \$150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting

Person.

4. These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$151.00 to \$151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

6. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$152.00 to \$152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.

7. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$153.02 to \$153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.

8. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$154.00 to \$154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.

9. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$155.23 to \$155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.

10. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$156.26 to \$156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.

Remarks:

1/2: Since there are more than 30 rows associated with the applicable transactions and EDGAR will not allow for the entry of more than 30 rows on a single Form 4, this Form 4 is being filed in conjunction with a second Form 4 by the Reporting Person. The two Form 4s filed by the Reporting Person on the date hereof should be read together as one consolidated filing.

/s/ Robin L. Praeger, attorney-
in-fact for Bradley Bolzon 06/30/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.